Time to get serious with HIV-1 resistance in sub-Saharan Africa

In The Lancet Infectious Diseases, John Gregson and colleagues report the results of a meta-analysis investigating HIV-1 drug resistance in 20 studies from sub-Saharan Africa.1 Gregson and colleagues included patients with failure of first-line tenofovir disproxil fumarate (TDF)-containing antiretroviral treatment (ART) regimens that also included first generation (nevirapine and efavirenz) non-nucleoside reverse transcriptase inhibitors (NNRTI) and a cytosine analogue (lamivudine or emtricitabine)—the WHO-recommended first-line ART regimen.